Korean drugmakers hold over 50% market share in the 6 best-selling biosimilar markets, 2 companies sign exclusive licensing ...
Teva and Celltrion’s attempt to muscle in on the multi-billion dollar US cancer and inflammatory disease drug market has hit a setback after the FDA rejected two key biosimilars because of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback